UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029648
Receipt number R000033676
Scientific Title Portal hemodynamic effects of regorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study
Date of disclosure of the study information 2017/11/01
Last modified on 2020/04/26 11:25:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Portal hemodynamic effects of regorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study

Acronym

Portal hemodynamic effects of regorafenib

Scientific Title

Portal hemodynamic effects of regorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study

Scientific Title:Acronym

Portal hemodynamic effects of regorafenib

Region

Japan


Condition

Condition

patients with advanced hepatocellular carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of the portal hemodynamic effect of regorafenib in patients with advanced HCC

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in portal venous area

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Regorafenib 160 mg per day for 2 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

Advanced-stage HCC is confirmed by radiological analysis. Patients were classified as having advanced-stage HCC if they were not eligible for or had disease progression after surgical or locoregional therapies.

Key exclusion criteria

Tumor invasion in intrahepatic large vessels was classified according to the criteria of the Liver Cancer Study of Japan as portal tumor invasion involving first-order-branches (Vp3) and the main trunk of the portal vein (Vp4), or as tumor invasion involving first-order branches of the hepatic vein (Vv2) and the inferior vena cava (Vv3).

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Hisashi
Middle name
Last name HIDAKA

Organization

Kitasato University School of Medicine

Division name

Department of Gastroenterology, Internal Medicine

Zip code

252-0374

Address

1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0380, Japan

TEL

+81-42-778-7750

Email

hisashi7@kitasato-u.ac.jp


Public contact

Name of contact person

1st name Hisashi
Middle name
Last name HIDAKA

Organization

Kitasato University School of Medicine

Division name

Department of Gastroenterology, Internal Medicine

Zip code

252-0380

Address

1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0380, Japan

TEL

+81-42-778-7750

Homepage URL


Email

hisashi7@kitasato-u.ac.jp


Sponsor or person

Institute

Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kitasato University ethical communiity

Address

1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0380, Japan

Tel

+81-42-778-8111

Email

rinri@med.kitasato-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

3

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 10 Month 01 Day

Date of IRB

2017 Year 10 Month 01 Day

Anticipated trial start date

2017 Year 11 Month 01 Day

Last follow-up date

2019 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 10 Month 21 Day

Last modified on

2020 Year 04 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033676


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name